| 4.305 0.02 (0.47%) | 10-23 11:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.1 | 1-year : | 7.13 |
| Resists | First : | 5.22 | Second : | 6.1 |
| Pivot price | 4.18  |
|||
| Supports | First : | 3.52 | Second : | 2.47 |
| MAs | MA(5) : | 4.51  |
MA(20) : | 3.9 |
| MA(100) : | 2.99 |
MA(250) : | 3.19 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 59.1 |
D(3) : | 67.7 |
| RSI | RSI(14): 59.1 |
|||
| 52-week | High : | 6.32 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABSI ] has closed below upper band by 42.6%. Bollinger Bands are 126.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.63 - 4.66 | 4.66 - 4.68 |
| Low: | 4.06 - 4.09 | 4.09 - 4.12 |
| Close: | 4.23 - 4.28 | 4.28 - 4.33 |
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Wed, 22 Oct 2025
Certain Stock Options of Absci Corporation are subject to a Lock-Up Agreement Ending on 23-OCT-2025. - MarketScreener
Wed, 22 Oct 2025
ARK Investment Management LLC Lowers Stake in Absci Corporation $ABSI - MarketBeat
Sun, 19 Oct 2025
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Thu, 16 Oct 2025
Absci (ABSI) Accelerates ABS-201 Trials for Hair Loss—Is Its AI Drug Pipeline Turning a Corner? - Sahm
Thu, 16 Oct 2025
Absci Corporation (ABSI) Stock Report: Exploring a 62% Potential Upside in AI-Powered Drug Development - DirectorsTalk Interviews
Mon, 13 Oct 2025
Absci’s AI Drug Platform Hopes To Catch Up With Investor Hype - Finimize
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 150 (M) |
| Held by Insiders | 1.3204e+008 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 31,610 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0373e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 293.9 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 4.14e+006 % |
| Gross Profit (p.s.) | -25.63 |
| Sales Per Share | -27.59 |
| EBITDA (p.s.) | -3.2524e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.16 |
| Price to Cash Flow | 6.61 |
| Dividend | 0 |
| Forward Dividend | 3.304e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|